Benjamin L. Palleiko, the chief executive officer of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), recorded insider transactions involving the company's common stock on April 16 and April 17, 2026, according to filings disclosed by the company.
On April 16, 2026, Palleiko received 20,312 shares of KalVista common stock through the settlement of an equal number of Restricted Stock Units (RSUs). Each RSU in the settled grant entitles the holder to receive one share of common stock at settlement without payment. The filings state that the RSU grant vests in scheduled installments - specifically, 1/16th of the total shares covered by the award vest on each quarterly anniversary of the Vesting Commencement Date, beginning April 16, 2026, and vesting is conditioned on continued service.
The following day, April 17, 2026, Palleiko sold 9,550 of those shares for proceeds totaling $193,065. The per-share price reported for that sale was $20.2163. The filing classifies the disposition as a "sell to cover," a transaction conducted to satisfy tax withholding obligations associated with the RSU vesting and settlement, rather than a discretionary sale initiated by the CEO.
After these transactions, Palleiko's direct holdings in KalVista common stock amount to 462,577 shares. He is also reported to hold 304,688 unvested RSUs.
Market context included with the filing highlights that KalVista's shares have recently traded near a 52-week high of $21.30, reflecting a 74% gain over the past year. The timing of the sell-to-cover coincided with this elevated trading level.
Third-party valuation commentary included in the disclosure notes that InvestingPro's analysis regards the stock as undervalued at current levels, with the platform's Fair Value assessment suggesting additional upside. The filing also notes that four analysts have recently increased their earnings estimates for KalVista. The filing mentions that InvestingPro provides Pro Research Reports on KALV and over 1,400 U.S. equities.
The insider transaction disclosure was accompanied by a summary of recent company performance and analyst reactions. KalVista reported strong fourth-quarter fiscal 2025 results, with Ekterly sales of $35 million that exceeded consensus expectations of $21 million. During the quarter the company launched 1,318 start forms, covering roughly 11% of the U.S. diagnosed population for the condition targeted by Ekterly.
KalVista also presented interim data from its KONFIDENT-KID study, which assesses Ekterly in children aged 2-11 with hereditary angioedema. The interim results cited a median time to treatment of 25 minutes.
Analyst responses to these developments were mixed but generally constructive. Citizens reiterated a Market Outperform rating but trimmed its price target modestly to $28, citing steady launch outcomes. H.C. Wainwright maintained a Buy rating with a $37 target and commented that Ekterly is changing the on-demand treatment landscape for hereditary angioedema. Stifel increased its price target to $42, pointing to strong demand for Ekterly and characterizing the therapy as a market-shaping product.
KalVista's fiscal year 2025 revenues were reported at $49 million, reinforcing the company narrative around Ekterly's commercial impact during that period.
The filings and accompanying commercial and analyst disclosures provide a snapshot of an executive-level equity settlement and a routine sell-to-cover that reduced the newly settled position to satisfy tax obligations. They also place the share movement in the context of recent commercial momentum for Ekterly and differing external valuation and forecast views from research providers and analysts.